{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:52:40Z","timestamp":1781632360747,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009614","name":"University of Rhode Island","doi-asserted-by":"publisher","award":["Office of the Undergraduate Research"],"award-info":[{"award-number":["Office of the Undergraduate Research"]}],"id":[{"id":"10.13039\/100009614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R21NS134813"],"award-info":[{"award-number":["R21NS134813"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cannabis Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Stroke is a leading cause of death and disability worldwide, but therapeutic options to reduce or prevent neuronal damage are extremely limited. Cannabinoids exhibit antioxidant, anti-inflammatory, and receptor modulatory actions that may offer neuroprotection. While research on the potential of cannabinoids has expanded in epilepsy and neurodegeneration, the neuroprotective potential of this class of natural compounds in stroke remains underexplored. Here, we evaluated a panel of phytocannabinoids (PCs) for their ability to mitigate ischemia\u2013reperfusion injury in an in vitro human model of stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Human induced pluripotent stem cell (iPSC)-derived cortical neurons were subjected to 60\u00a0min of oxygen\u2013glucose deprivation (OGD) followed by reperfusion. Neuronal survival was quantified over seven days using longitudinal live-cell imaging. Twenty-eight PCs were screened for their effect on reducing neuronal death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 28 PCs screened, seven demonstrated modest effects, with cannabigerorcinic acid (CBGOA) significantly improving post-OGD neuronal survival. While OGD exposure led to increased cell death via activation of caspase 3, CBGOA treatment did not impact that pathway, suggesting that other caspase-independent pathways may be implicated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This pilot study identifies CBGOA as a candidate cannabinoid with neuroprotective potential in an in vitro model of ischemic stroke. The use of iPSC-derived human cortical neurons strengthens translational relevance, but the modest effects observed, and the limitations of in vitro systems, underscore the need for in vivo validation and further mechanistic studies. Collectively, these results provide a foundation for exploring CBGOA and related cannabinoids as potential neuroprotective agents in stroke.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42238-026-00393-0","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:45:58Z","timestamp":1769157958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring the neuroprotective effects of phytocannabinoids on oxygen-glucose deprived neurons in an in vitro model of stroke"],"prefix":"10.1186","volume":"8","author":[{"given":"Bhavya","family":"Chatragadda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Potts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fallini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"issue":"2","key":"393_CR1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1177\/17474930241308142","volume":"20","author":"VL Feigin","year":"2025","unstructured":"Feigin VL, Brainin M, Norrving B, Martins SO, Pandian J, Lindsay P, et al. World stroke organization: global stroke fact sheet 2025. Int J Stroke. 2025;20(2):132\u201344.","journal-title":"Int J Stroke"},{"issue":"4","key":"393_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1001\/jamaneurol.2024.0190","volume":"81","author":"D Renedo","year":"2024","unstructured":"Renedo D, Acosta JN, Leasure AC, Sharma R, Krumholz HM, de Havenon A, et al. Burden of ischemic and hemorrhagic stroke across the US from 1990 to 2019. JAMA Neurol. 2024;81(4):394\u2013404.","journal-title":"JAMA Neurol"},{"key":"393_CR3","unstructured":"Stroke Reperfusion ARKMDVJ. Injury. 2025. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK564350\/."},{"key":"393_CR4","unstructured":"P C, R F. Pathophysiology of Reperfusion Injury. In 2011. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534267\/."},{"key":"393_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/B978-0-12-394309-5.00006-7","volume":"298","author":"T Kalogeris","year":"2012","unstructured":"Kalogeris T, Baines C, Krenz M, Korthuis R. Cell biology of ischemia\/reperfusion injury. Int Rev Cell Mol Biology. 2012;298:229\u2013317.","journal-title":"Int Rev Cell Mol Biology"},{"key":"393_CR6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.neuropharm.2017.12.030","volume":"134","author":"RN Kalaria","year":"2018","unstructured":"Kalaria RN. The pathology and pathophysiology of vascular dementia. Neuropharmacology. 2018;134:226\u201339.","journal-title":"Neuropharmacology"},{"key":"393_CR7","doi-asserted-by":"publisher","first-page":"616","DOI":"10.11622\/smedj.2019158","volume":"60","author":"S Chohan","year":"2019","unstructured":"Chohan S, Venkatesh P, How C. Long-term complications of stroke and secondary prevention. Singap M\u00e9d J. 2019;60:616\u201320.","journal-title":"Singap M\u00e9d J"},{"key":"393_CR8","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1161\/CIRCRESAHA.122.319951","volume":"130","author":"NS Rost","year":"2022","unstructured":"Rost NS, Brodtmann A, Pase MP, van Veluw SJ, Biffi A, Duering M, et al. Post-Stroke cognitive impairment and dementia. Circ Res. 2022;130:1252\u201371.","journal-title":"Circ Res"},{"key":"393_CR9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.5853\/jos.2016.01144","volume":"18","author":"JS Kim","year":"2016","unstructured":"Kim JS. Post-stroke mood and emotional disturbances. J Stroke. 2016;18:244\u201355.","journal-title":"J Stroke"},{"key":"393_CR10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3390\/molecules29020410","volume":"29","author":"AK Al-Khazaleh","year":"2024","unstructured":"Al-Khazaleh AK, Zhou X, Bhuyan DJ, M\u00fcnch GW, Al-Dalabeeh EA, Jaye K, et al. The neurotherapeutic arsenal in cannabis sativa. Molecules. 2024;29:410.","journal-title":"Molecules"},{"issue":"3","key":"393_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/pharmaceutics12030265","volume":"12","author":"F Calapai","year":"2020","unstructured":"Calapai F, Cardia L, Sorbara EE, Navarra M, Gangemi S, Calapai G, et al. Cannabinoids, Blood\u2013Brain Barrier, and brain disposition. Pharmaceutics. 2020;12(3):265.","journal-title":"Pharmaceutics"},{"key":"393_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.phrs.2019.01.009","volume":"141","author":"E Brook","year":"2019","unstructured":"Brook E, Mamo J, Wong R, Al-Salami H, Falasca M, Lam V, et al. Blood-brain barrier disturbances in diabetes-associated dementia: therapeutic potential for cannabinoids. Pharmacol Res. 2019;141:291\u20137.","journal-title":"Pharmacol Res"},{"issue":"1","key":"393_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.clim.2011.02.010","volume":"142","author":"AJ S\u00e1nchez","year":"2012","unstructured":"S\u00e1nchez AJ, Garc\u00eda-Merino A. Neuroprotective agents: cannabinoids. Clin Immunol. 2012;142(1):57\u201367.","journal-title":"Clin Immunol"},{"key":"393_CR14","doi-asserted-by":"publisher","first-page":"4330","DOI":"10.1111\/bph.15185","volume":"177","author":"NL Stone","year":"2020","unstructured":"Stone NL, Murphy AJ, England TJ, O\u2019Sullivan SE. A systematic review of minor phytocannabinoids with promising neuroprotective potential. Br J Pharmacol. 2020;177:4330\u201352.","journal-title":"Br J Pharmacol"},{"key":"393_CR15","doi-asserted-by":"publisher","first-page":"11258","DOI":"10.3390\/ijms252011258","volume":"25","author":"M Jurga","year":"2024","unstructured":"Jurga M, Jurga A, Jurga K, Ka\u017amierczak B, Ku\u015bmierczyk K, Chabowski M. Cannabis-Based phytocannabinoids: Overview, mechanism of Action, therapeutic Application, Production, and affecting environmental factors. Int J Mol Sci. 2024;25:11258.","journal-title":"Int J Mol Sci"},{"key":"393_CR16","doi-asserted-by":"publisher","first-page":"989717","DOI":"10.3389\/fphar.2022.989717","volume":"13","author":"S Bhunia","year":"2022","unstructured":"Bhunia S, Kolishetti N, Arias AY, Vashist A, Nair M. Cannabidiol for neurodegenerative disorders: A comprehensive review. Front Pharmacol. 2022;13:989717.","journal-title":"Front Pharmacol"},{"key":"393_CR17","doi-asserted-by":"publisher","first-page":"6570","DOI":"10.3390\/ijms26146570","volume":"26","author":"D Tomaszewska-Zaremba","year":"2025","unstructured":"Tomaszewska-Zaremba D, Gajewska A, Misztal T. Anti-Inflammatory effects of cannabinoids in therapy of neurodegenerative disorders and inflammatory diseases of the CNS. Int J Mol Sci. 2025;26:6570.","journal-title":"Int J Mol Sci"},{"issue":"18","key":"393_CR18","doi-asserted-by":"publisher","first-page":"6127","DOI":"10.3390\/molecules27186127","volume":"27","author":"C Liu","year":"2022","unstructured":"Liu C, Puopolo T, Li H, Cai A, Seeram NP, Ma H. Identification of SARS-CoV-2 main protease inhibitors from a library of minor cannabinoids by biochemical Inhibition assay and surface plasmon resonance characterized binding affinity. Molecules. 2022;27(18):6127.","journal-title":"Molecules"},{"issue":"1","key":"393_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40478-024-01778-z","volume":"12","author":"R Sirtori","year":"2024","unstructured":"Sirtori R, J Gregoire M, Potts M, Collins E, Donatelli A, Fallini L. LINC complex alterations are a key feature of sporadic and Familial ALS\/FTD. Acta Neuropathol Commun. 2024;12(1):69.","journal-title":"Acta Neuropathol Commun"},{"issue":"49","key":"393_CR20","doi-asserted-by":"publisher","first-page":"e2406998121","DOI":"10.1073\/pnas.2406998121","volume":"121","author":"M Jean Gregoire","year":"2024","unstructured":"Jean Gregoire M, Sirtori R, Donatelli L, Morgan Potts E, Collins A, Zamor D, et al. Early disruption of the CREB pathway drives dendritic morphological alterations in FTD\/ALS cortical neurons. Proc Natl Acad Sci U S A. 2024;121(49):e2406998121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"393_CR21","first-page":"e51","volume":"79","author":"MS Fernandopulle","year":"2018","unstructured":"Fernandopulle MS, Prestil R, Grunseich C, Wang C, Gan L, Ward ME. Transcription Factor-Mediated differentiation of human iPSCs into Neurons. Current protocols in cell biology \/ editorial board. Juan S Bonifacino. 2018;79(1):e51.","journal-title":"Juan S Bonifacino"},{"issue":"2","key":"393_CR22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.neuron.2019.07.014","volume":"104","author":"R Tian","year":"2019","unstructured":"Tian R, Gachechiladze MA, Ludwig CH, Laurie MT, Hong JY, Nathaniel D, et al. CRISPR Interference-Based platform for multimodal genetic screens in human iPSC-Derived neurons. Neuron. 2019;104(2):239\u2013e25512.","journal-title":"Neuron"},{"key":"393_CR23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/978-1-4939-2152-2_15","volume":"1254","author":"CI Tasca","year":"2014","unstructured":"Tasca CI, Dal-Cim T, Cimarosti H. Neuronal cell Death, methods and protocols. Methods Mol Biol. 2014;1254:197\u2013210.","journal-title":"Methods Mol Biol"},{"key":"393_CR24","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1523\/JNEUROSCI.13-08-03510.1993","volume":"13","author":"M Goldberg","year":"1993","unstructured":"Goldberg M, Choi D. Combined oxygen and glucose deprivation in cortical cell culture. J Neurosci. 1993;13:3510\u201324.","journal-title":"J Neurosci"},{"issue":"7","key":"393_CR25","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676\u201382.","journal-title":"Nat Methods"},{"key":"393_CR26","doi-asserted-by":"publisher","unstructured":"Reggio PH. Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown. Curr Med Chem. 2010;17(14):1468\u201386. https:\/\/doi.org\/10.2174\/092986710790980005.","DOI":"10.2174\/092986710790980005"},{"issue":"1","key":"393_CR27","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1124\/jpet.110.168237","volume":"335","author":"A Alhamoruni","year":"2010","unstructured":"Alhamoruni A, Lee AC, Wright KL, Larvin M, O\u2019Sullivan SE. Pharmacological effects of cannabinoids on the Caco-2 cell culture model of intestinal permeability. J Pharmacol Exp Ther. 2010;335(1):92\u2013102.","journal-title":"J Pharmacol Exp Ther"},{"key":"393_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s42238-021-00113-w","volume":"4","author":"LL Anderson","year":"2022","unstructured":"Anderson LL, Udoh M, Everett-Morgan D, Heblinski M, McGregor IS, Banister SD, et al. Olivetolic acid, a cannabinoid precursor in cannabis sativa. J Cannabis Res. 2022;4:2.","journal-title":"J Cannabis Res"},{"key":"393_CR29","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/aps.2009.24","volume":"30","author":"X Dong","year":"2009","unstructured":"Dong X xia, Wang Y, Qin Zzhong. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin. 2009;30:379\u201387.","journal-title":"Acta Pharmacol Sin"},{"key":"393_CR30","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1161\/01.STR.29.3.705","volume":"29","author":"T Kristi\u00e1n","year":"1998","unstructured":"Kristi\u00e1n T, Siesj\u00f6 BK. Calcium in ischemic cell death. Stroke. 1998;29:705\u201318.","journal-title":"Stroke"},{"key":"393_CR31","doi-asserted-by":"publisher","first-page":"5431","DOI":"10.3390\/ijms22115431","volume":"22","author":"LA Kasatkina","year":"2021","unstructured":"Kasatkina LA, Rittchen S, Sturm EM. Neuroprotective and Immunomodulatory action of the endocannabinoid system under neuroinflammation. Int J Mol Sci. 2021;22:5431.","journal-title":"Int J Mol Sci"},{"key":"393_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.14581\/jer.17012","volume":"7","author":"E Perucca","year":"2017","unstructured":"Perucca E. Cannabinoids in the treatment of epilepsy: hard evidence at last? J Epilepsy Res. 2017;7:61\u201376.","journal-title":"J Epilepsy Res"},{"key":"393_CR33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fphar.2014.00037","volume":"5","author":"E Aso","year":"2014","unstructured":"Aso E, Ferrer I. Cannabinoids for treatment of alzheimer\u2019s disease: moving toward the clinic. Front Pharmacol. 2014;5:37.","journal-title":"Front Pharmacol"},{"key":"393_CR34","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2125.2012.04341.x","volume":"75","author":"J Fern\u00e1ndez-Ruiz","year":"2013","unstructured":"Fern\u00e1ndez-Ruiz J, Sagredo O, Pazos MR, Garc\u00eda C, Pertwee R, Mechoulam R, et al. Cannabidiol for neurodegenerative disorders. Br J Clin Pharmacol. 2013;75:323\u201333.","journal-title":"Br J Clin Pharmacol"},{"key":"393_CR35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/antiox9010021","volume":"9","author":"S Atalay","year":"2019","unstructured":"Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and Anti-Inflammatory properties of Cannabidiol. Antioxidants. 2019;9:21.","journal-title":"Antioxidants"},{"key":"393_CR36","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1088208","volume":"302","author":"G Marsicano","year":"2003","unstructured":"Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, et al. CB1 cannabinoid receptors and On-Demand defense against excitotoxicity. Science. 2003;302:84\u20138.","journal-title":"Science"},{"key":"393_CR37","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1038\/nprot.2012.116","volume":"7","author":"Y Shi","year":"2012","unstructured":"Shi Y, Kirwan P, Livesey FJ. Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat Protoc. 2012;7:1836\u201346.","journal-title":"Nat Protoc"},{"key":"393_CR38","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.stem.2016.05.022","volume":"18","author":"I Kelava","year":"2016","unstructured":"Kelava I, Lancaster MA. Stem cell models of human brain development. Cell Stem Cell. 2016;18:736\u201348.","journal-title":"Cell Stem Cell"},{"key":"393_CR39","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1023\/B:MEBR.0000043966.46964.e6","volume":"19","author":"P Mergenthaler","year":"2004","unstructured":"Mergenthaler P, Dirnagl U, Meisel A. Pathophysiology of stroke: lessons from animal models. Metab Brain Dis. 2004;19:151\u201367.","journal-title":"Metab Brain Dis"},{"key":"393_CR40","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1161\/STROKEAHA.108.541128","volume":"40","author":"M Fisher","year":"2009","unstructured":"Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40:2244\u201350.","journal-title":"Stroke"}],"container-title":["Journal of Cannabis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42238-026-00393-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-026-00393-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-026-00393-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:00:33Z","timestamp":1781629233000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42238-026-00393-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["393"],"URL":"https:\/\/doi.org\/10.1186\/s42238-026-00393-0","relation":{},"ISSN":["2522-5782"],"issn-type":[{"value":"2522-5782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"H.M. serves as a guest editor of a Collection (Non-Psychotropic Cannabinoids in Drug Discovery and Their Therapeutic Potential) in Journal of Cannabis Research. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}